IB2 Antikörper (AA 31-130) (Biotin)

Produktnummer ABIN1700887

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch IB2 in WB, ELISA, IHC (p) und IHC (fro). Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für IB2 Antikörper (AA 31-130) (Biotin) (ABIN1700887)

Target: IB2 (JIP-2) (C-Jun-Amino-Terminal Kinase-Interacting Protein 2 (JIP-2))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IB2 Antikörper ist konjugiert mit Biotin

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Produktdetails anti-IB2 Antikörper (Biotin)

Bindungsspezifität: AA 31-130

Homologie: Human,Mouse,Rat,Cow,Horse

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human JIP2

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C for 12 months.

Haltbarkeit: 12 months

Details zu IB2

Target: IB2 (JIP-2) (C-Jun-Amino-Terminal Kinase-Interacting Protein 2 (JIP-2))

Andere Bezeichnung: JIP2

Hintergrund:

Synonyms: MAPK8IP2, C jun amino terminal kinase interacting protein 2, C-jun-amino-terminal kinase-interacting protein 2, Homologous to mouse JIP 1, IB 2, IB-2, IB2, Islet brain 2, Islet-brain-2, JIP 2, JIP-2, JIP2, JIP2_HUMAN, JNK interacting protein 2, JNK MAP kinase scaffold protein 2, JNK MAP kinase scaffold protein JIP2, JNK-interacting protein 2, MAPK8IP2, Mitogen activated protein kinase 8 interacting protein 2, Mitogen-activated protein kinase 8-interacting protein 2, PRKM8 interacting protein like, PRKM8IPL.

Background: c-Jun NH2-terminal kinases (JNKs) are distant members of the MAP kinase family (1). JNK1 is activated by dual phosphorylation at a Thr-Pro-Tyr motif in response to ultraviolet (UV) light, and it functions to phosphorylate c-Jun at amino terminal serine regulatory sites, Ser-63 and Ser-73, resulting in transcriptional activation (2-5). Two additional JNK family members have been identified as JNK2 and JNK3 (3). JIP-1 (for JNK interacting protein-1) has been identified as a cytoplasmic inhibitor of JNK that retains JNK in the cytoplasm, thereby inhibiting JNK-regulated gene expression. Evidence suggests that JNK1 and JNK2 bind to JIP-1 with greater affinity than to ATF-2 and c-Jun, which are targets of the JNK signaling pathway. JIP-1 contains an amino terminal JNK binding domain and a carboxy terminal SH3 domain. ATF-2 and c-Jun also contain the JNK binding domain and are thought to compete with JIP-1 for JNK binding (6). Multiple splice variants if JIP-1, including JIP-1b, JIP-1c (also designated islet-brain 1 or IB-1), JIP-2a, JIP-2b and JIP-3, have been identified in brain (7).